Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma.
other
Where this comes from
- Record sourced from PubMed, PMID 21383985.
- Also identified by DOI 10.1371/journal.pone.0016408 and PMC identifier 3044711.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
BACKGROUND: We undertook a study to evaluate the clinical relevance of miR-92a in plasma obtained from non-Hodgkin's lymphoma (NHL) patients, because the miR-17-92 polycistronic miRNA cluster plays a crucial role in lymphomagenesis and affects neo-angiogenesis. METHODOLOGY/PRINCIPAL FINDINGS: Plasma miR-92a values in NHL were extremely low (<5%), compared with healthy subjects (P<.0001), irrespective of lymphoma sub-type. The very low plasma level of miR-92a increased in the complete response (CR) phase but did not reach the normal range, and the plasma level was lower again in the relapse phase. Patients in CR or CR unconfirmed with a plasma miR-92a level of less than the cut-off level showed a significantly high relapse rate compared with patients with normalized plasma miR-92a level. CONCLUSIONS/SIGNIFICANCE: The current results therefore indicate that the plasma miR-92a value could be a novel biomarker not only for diagnosis but also for monitoring lymphoma patients after chemotherapy.
Medical subject headings
- Lymphoma, Non-Hodgkin
- MicroRNAs